Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,191JPY
2:00am EDT
Change (% chg)

¥76 (+1.24%)
Prev Close
¥6,115
Open
¥6,140
Day's High
¥6,199
Day's Low
¥6,131
Volume
1,997,300
Avg. Vol
1,906,236
52-wk High
¥6,199
52-wk Low
¥4,321

Latest Key Developments (Source: Significant Developments)

AstraZeneca, Takeda collaborate to develop, commercialise MEDI1341 for Parkinson's disease
Tuesday, 29 Aug 2017 02:05am EDT 

Aug 29 (Reuters) - AstraZeneca Plc :ASTRAZENECA AND TAKEDA ESTABLISH COLLABORATION TO DEVELOP AND COMMERCIALISE MEDI1341 FOR PARKINSON'S DISEASE.PARTIES ENTERS DEAL TO DEVELOP, COMMERCIALISE MEDI1341, ALPHA-SYNUCLEIN ANTIBODY CURRENTLY IN DEVELOPMENT AS POTENTIAL TREATMENT FOR PARKINSON'S DISEASE.  Full Article

Takeda and Shattuck Labs announce research collaboration
Thursday, 10 Aug 2017 09:00am EDT 

Aug 10 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Takeda and Shattuck Labs announce research collaboration to explore agonist redirected checkpoint fusion proteins in immuno-oncology.Takeda says it will hold options for exclusive global development and commercialization rights for up to four molecules resulting from collaboration​.Says ‍collaboration will include two pre-clinical and four discovery stage programs​.Says it ‍will provide funding for pre-clinical and clinical development​.‍Additional terms of collaboration are not disclosed​.  Full Article

Takeda Pharmaceutical and Molecular Templates announce research and licensing collaboration
Thursday, 3 Aug 2017 09:00am EDT 

Aug 3 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Takeda Pharmaceutical and molecular templates announce multi-target research and licensing collaboration to develop next-generation oncology therapies​.Takeda Pharmaceutical - ‍collaboration will apply molecular templates' engineered toxin bodies technology platform to potential therapeutic targets provided by takeda​.Takeda Pharmaceutical Co - Takeda will have right to exercise exclusive options to obtain license rights to products resulting from collaboration.Takeda Pharmaceutical Co Ltd says additional terms of agreement are not being disclosed.Takeda Pharmaceutical says it will make an equity investment and molecular templates is eligible to receive upfront payments, milestone payments​.Says ‍signed the agreement through its wholly owned subsidiary, millennium pharmaceuticals​.  Full Article

Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology
Thursday, 27 Jul 2017 11:21am EDT 

July 27 (Reuters) - Infinity Pharmaceuticals Inc ::Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology.Co says it has amended its license agreement with Takeda Oncology for IPI-549.Co will no longer have obligation to pay Takeda on worldwide net sales of selective inhibitors of PI3K-Gamma.Co remains obligated to pay development, regulatory and commercial milestones to Takeda for IPI-549.  Full Article

Takeda, Schrödinger announce multi-year, multi-target research collaboration
Thursday, 20 Jul 2017 09:00am EDT 

July 20 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::Takeda and Schrödinger announce multi-year, multi-target research collaboration.Says under novel collaboration approach, Schrödinger will autonomously lead discovery efforts.Says under terms of collaboration, Takeda will have option to exclusively license programs from Schrödinger.Takeda Pharmaceutical Co Ltd - additional financial details are not being disclosed.Takeda Pharmaceutical - economic terms include pre-clinical, clinical, and commercial milestones of up to $170 million per program, as well as royalties on future sales.  Full Article

Prana Biotechnology announces research collaboration with Takeda Pharmaceuticals
Monday, 17 Jul 2017 08:05pm EDT 

July 18 (Reuters) - Prana Biotechnology:announced a research collaboration with Takeda Pharmaceuticals International, Inc.  Full Article

Selexis announces commercial license agreement with Takeda
Tuesday, 27 Jun 2017 08:00am EDT 

June 27 (Reuters) - :Selexis announces commercial license agreement with Takeda for the development of fusion proteins.  Full Article

Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial
Monday, 26 Jun 2017 06:45am EDT 

June 26 (Reuters) - Seattle Genetics Inc :Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial evaluating Adcetris in frontline advanced hodgkin lymphoma.Says interim analysis of overall survival, key secondary endpoint, also trended in favor of Adcetris+AVD arm.Says safety profile of Adcetris+AVD in trial was consistent with that known for single-agent components of regimen.Says there was an increased incidence of febrile neutropenia and peripheral neuropathy in the Adcetris+AVD arm.Takeda and Seattle Genetics plan to submit trial results to regulatory authorities for approval in respective territories.phase 3 clinical trial met primary endpoint of statistically significant improvement in modified progression-free survival versus control arm.  Full Article

Swissmedic acceptes Takeda and Tigenix's file on Cx601 for review
Tuesday, 20 Jun 2017 01:18am EDT 

June 20 (Reuters) - TIGENIX NV ::TAKEDA <<<4502.T>>> AND TIGENIX ANNOUNCE THAT SWISSMEDIC HAS ACCEPTED FOR REVIEW THE FILE ON CX601 FOR THE TREATMENT OF COMPLEX PERIANAL FISTULAS IN CROHN’S DISEASE PATIENTS.  Full Article

Wilex says unit Heidelberg Pharma signs research agreement with Takeda
Monday, 19 Jun 2017 11:14am EDT 

June 19 (Reuters) - WILEX AG ::SUBSIDIARY HEIDELBERG PHARMA SIGNS EXCLUSIVE MULTI-TARGET RESEARCH AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT OF ANTIBODY TARGETED AMANITIN CONJUGATES.‍UNDER TERMS OF AGREEMENT, HEIDELBERG PHARMA WILL PRODUCE ANTIBODY TARGETED AMANITIN CONJUGATES (ATACS) USING ANTIBODIES FROM TAKEDA'S PROPRIETARY PORTFOLIO FOR UP TO THREE UNDISCLOSED TARGETS​.‍UNDER LICENSE AGREEMENT, HEIDELBERG PHARMA WOULD BE ELIGIBLE TO RECEIVE CLINICAL DEVELOPMENT, REGULATORY AND SALES-RELATED MILESTONE PAYMENTS OF UP TO USD 113 MILLION FOR EACH PRODUCT CANDIDATE, AS WELL AS ROYALTIES​.  Full Article

Photo

Fujifilm says aims to spend $4.5 billion on M&A over three years

TOKYO Fujifilm Holdings Corp said it aimed to spend 500 billion yen ($4.54 billion) in strategic acquisitions over three years as it seeks growth outside its traditional photographic film business, which has been shrinking.